Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Coya Therapeutics (COYA) EBITDA Margin (2023 - 2025)

Coya Therapeutics (COYA) has disclosed EBITDA Margin for 3 consecutive years, with 304.91% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin fell 50686876.0% to 304.91% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 55.75% through Dec 2025, up 3567.0% year-over-year, with the annual reading at 55.75% for FY2025, 3567.0% up from the prior year.
  • EBITDA Margin hit 304.91% in Q4 2025 for Coya Therapeutics, up from 68.07% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 507173.67% in Q4 2024 to a low of 4317.45% in Q1 2024.
  • Historically, EBITDA Margin has averaged 62017.33% across 3 years, with a median of 81.17% in 2025.
  • Biggest five-year swings in EBITDA Margin: soared 50714331bps in 2024 and later tumbled -50686876bps in 2025.
  • Year by year, EBITDA Margin stood at 30.36% in 2023, then skyrocketed by 1670684bps to 507173.67% in 2024, then crashed by -100bps to 304.91% in 2025.
  • Business Quant data shows EBITDA Margin for COYA at 304.91% in Q4 2025, 68.07% in Q3 2025, and 3916.29% in Q2 2025.